Robert Lorne Hopfner
CIK 1551966 · last filed 2026-10-14
Robert Lorne Hopfner is a corporate insider who has filed 33 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing shows the insider exercised options covering $109.9K of RLYB on Oct 14, 2026. Across all open-market trades the lifetime net is +$3.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $108.9M across reported positions. 13 SEC filings were submitted jointly with Inozyme Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PCVX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
750 BATTERY STREET, SUITE 400
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLYB | Director | 220,994 | $15.90 | $3.51M | $7.50M | 8 | 2026-10-14 |
| EVMN | Director | 294,502 | $6.04 | $1.78M | $17.4K | 1 | 2025-12-22 |
| Inozyme Pharma, Inc. (INZY) Delisted | Director | 2,923,110 | $4.00 | $11.69M | $16.20M | 11 | 2024-06-20 |
| PCVX | Director | 1,577,316 | $65.68 | $103.60M | -$20.55M | 11 | 2021-06-03 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-14 | RLYB | Exer (M) | +14,820 | $109.9K | EDGAR |
| 2025-12-22 | EVMN | Buy (P) | +1,000 | $17.4K | EDGAR |
| 2025-11-12 | — | Conv (C) | +3,371,001 | $0 | |
| 2025-07-03 | — | U | −4,494,851 | -$17.98M | |
| 2025-05-15 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-17 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2023-08-03 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +833,333 | $4.00M | EDGAR |
| 2023-06-15 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.